BR0212522A - Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco - Google Patents

Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco

Info

Publication number
BR0212522A
BR0212522A BR0212522-6A BR0212522A BR0212522A BR 0212522 A BR0212522 A BR 0212522A BR 0212522 A BR0212522 A BR 0212522A BR 0212522 A BR0212522 A BR 0212522A
Authority
BR
Brazil
Prior art keywords
insulin
binding ligand
zinc binding
action
insulin preparation
Prior art date
Application number
BR0212522-6A
Other languages
English (en)
Inventor
Helle Birk Olsen
Niels C Kaarsholm
Peter Madsen
S Ren Istergaard
Svend Ludvigsen
Palle Jakobsen
Anders Klarskov Petersen
Dorte Bjerre Steensgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0212522A publication Critical patent/BR0212522A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"LIGANDO DE LIGAçãO DE ZINCO, HEXâMERO DE INSULINA, PREPARAçãO AQUOSA DE INSULINA E MéTODOS DE PROLONGAR A AçãO DE UMA PREPARAçãO DE INSULINA E DE PREPARAR UM LIGANDO DE LIGAçãO DE ZINCO". Novos ligandos para os sítios HISB10 Zn^ 2+^ do hexâmero de insulina de estado R que são capazes de prolongar a ação das preparações de insulina são divulgados.
BR0212522-6A 2001-09-14 2002-09-13 Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco BR0212522A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101337 2001-09-14
US32392501P 2001-09-21 2001-09-21
DKPA200201066 2002-07-05
US39605102P 2002-07-10 2002-07-10
PCT/DK2002/000595 WO2003027081A2 (en) 2001-09-14 2002-09-13 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER

Publications (1)

Publication Number Publication Date
BR0212522A true BR0212522A (pt) 2004-08-10

Family

ID=27439845

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212522-6A BR0212522A (pt) 2001-09-14 2002-09-13 Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco

Country Status (15)

Country Link
US (1) US7879893B2 (pt)
EP (1) EP1429763B1 (pt)
JP (1) JP4554207B2 (pt)
CN (1) CN1558762A (pt)
AT (1) ATE363278T1 (pt)
BR (1) BR0212522A (pt)
CA (1) CA2460541A1 (pt)
CZ (1) CZ2004313A3 (pt)
DE (1) DE60220424T2 (pt)
ES (1) ES2288195T3 (pt)
HU (1) HUP0401492A3 (pt)
MX (1) MXPA04002404A (pt)
NO (1) NO20041494L (pt)
PL (1) PL369119A1 (pt)
WO (1) WO2003027081A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040063098A1 (en) * 2002-09-26 2004-04-01 Hargreaves John S. Methods for producing multilayer ligand arrays
US20060276520A1 (en) * 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
ATE378063T1 (de) * 2002-12-20 2007-11-15 Novo Nordisk As Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7781464B2 (en) 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
WO2004080480A1 (en) * 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
AU2004256124B2 (en) * 2003-07-02 2011-04-28 Corus Pharma, Inc. Aztreonam L-lysine and methods for the preparation thereof
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US7037927B2 (en) * 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005054291A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
US7880009B2 (en) * 2004-05-26 2011-02-01 Eisai R&D Management Co., Ltd. Cinnamide compound
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
EP1768694A1 (en) * 2004-07-09 2007-04-04 Novo Nordisk A/S Phamaceutical preparations comprising insulin
RU2007106180A (ru) * 2004-08-05 2008-09-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные индола, индазола или индолина
WO2006029634A2 (en) * 2004-09-17 2006-03-23 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
MX2007003735A (es) * 2004-09-28 2007-04-23 Otsuka Pharma Co Ltd Compuesto de carboestirilo.
EP1808432B1 (en) 2004-10-26 2010-02-24 Eisai R&D Management Co., Ltd. Amorphous form of cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TW200800978A (en) * 2006-03-23 2008-01-01 Otsuka Pharma Co Ltd Carbazole compound
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
PE20081791A1 (es) 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
BRPI0815773A2 (pt) 2007-08-31 2019-09-24 Eisai R&D Man Co Ltd composto, e, medicamento.
CN104125948A (zh) 2012-02-21 2014-10-29 拜耳知识产权有限责任公司 具有除草活性的4-硝基-取代的n-(四唑-5-基)芳基羧酸酰胺、n-(三唑-5-基)芳基羧酸酰胺以及n-(1,3,4-噁二唑-2-基)芳基羧酸酰胺
US9447069B2 (en) * 2012-04-30 2016-09-20 Innov17 Llc ROR modulators and their uses
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
JP6156845B2 (ja) * 2014-03-04 2017-07-05 株式会社島津製作所 マトリックス支援レーザ脱離イオン化質量分析用マトリックス
US10017520B2 (en) * 2014-12-10 2018-07-10 Massachusetts Institute Of Technology Myc modulators and uses thereof
AU2015360291A1 (en) 2014-12-11 2017-07-13 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
EP3282846A4 (en) * 2015-03-23 2018-09-26 University of Miami Inhibitors of the notch transcriptional activation complex and methods for use of the same
AU2017221422A1 (en) 2016-02-16 2018-08-16 Massachusetts Institute Of Technology MAX binders as Myc modulators and uses thereof
US11046683B2 (en) * 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
JP2002529514A (ja) * 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物

Also Published As

Publication number Publication date
CN1558762A (zh) 2004-12-29
JP2005508335A (ja) 2005-03-31
JP4554207B2 (ja) 2010-09-29
NO20041494L (no) 2004-04-13
HUP0401492A3 (en) 2008-05-28
PL369119A1 (en) 2005-04-18
HUP0401492A2 (hu) 2004-11-29
EP1429763B1 (en) 2007-05-30
WO2003027081A2 (en) 2003-04-03
CA2460541A1 (en) 2003-04-03
MXPA04002404A (es) 2004-05-31
US7879893B2 (en) 2011-02-01
US20030229120A1 (en) 2003-12-11
CZ2004313A3 (cs) 2004-07-14
DE60220424T2 (de) 2008-03-06
WO2003027081A3 (en) 2004-03-25
DE60220424D1 (de) 2007-07-12
ES2288195T3 (es) 2008-01-01
ATE363278T1 (de) 2007-06-15
EP1429763A2 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
BR0212522A (pt) Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco
BRPI0408229A (pt) preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação
AU2003262877A1 (en) Wireless device operating system (os) application programmer's interface (api)
AU2214600A (en) Spring-powered infusion pump
TR200000654T2 (tr) KAY-Yeni bir bağışıklık sistemi proteini.
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
CY1110547T1 (el) Συμπυκνωμενα πρωτεϊνικα σκευασματα μειωμενου ιξωδους
DK160633C (da) Slangepumpe, isaer til avendelse som insulinpumpe
AR025247A1 (es) Composiciones de granulos de carotenos-xantofilos, estables
BR0005321B1 (pt) bomba peristÁltica e cartucho.
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
AU2003291972A1 (en) Pharmaceutical compositions comprising insulin and legends of insulin hexamer
MY134966A (en) Alkaline earth metal complexes and their use
ES2185196T3 (es) Un procedimiento para la preparacion de tetraazamacrociclos.
DE59911929D1 (de) Membrankolbenpumpe
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
MXPA04000068A (es) Conjugados de progenipoyetina modificados quimicamente.
BR0101437A (pt) Método para preparar um ciclopropeno
DE69805002D1 (de) Kv2.1 antagonisten
BG103779A (en) Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid
DE58901449D1 (de) Tauchkolbenkompressor.
ITTO980659A0 (it) Compressore alternativo.
TR199902605T2 (xx) Fibrinojenin azalt�lma y�ntemleri.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2094 DE 22/02/2011.